Lutein and Zeaxanthin for Macular Degeneration — What Does the Cochrane Review Actually Show?

Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss in older adults in developed countries. The disease affects the macula — a small but crucial area of the retina responsible for the sharp central vision needed for reading, recognizing faces, or driving. AMD usually develops slowly, over years, and can be completely asymptomatic in its early stages — the first sign is often distortion of straight lines or a dark spot in the center of the visual field, by which point the disease is already advanced.

There are two forms of AMD: dry (by far the more common, accounting for about 85-90% of cases, associated with gradual loss of retinal cells) and wet (rarer but more sudden, associated with abnormal blood vessel growth under the retina that can bleed and rapidly destroy central vision). This distinction matters for this article — the evidence discussed here concerns primarily slowing disease progression in people with intermediate-stage AMD, not treating already-developed wet AMD, which ophthalmologists today treat mainly with anti-VEGF injections into the eye.

Against this backdrop, a clear trend has existed for years in the supplement market: lutein and zeaxanthin sold as "vitamins for the eyes," often alongside promises of improved vision during screen work or general "eye protection." This article checks what the strongest available evidence — a 2023 Cochrane systematic review — actually says about lutein, zeaxanthin, and other antioxidants in the context of AMD, and where solid science ends and marketing oversimplification begins.

Lutein and zeaxanthin are carotenoids — pigments from the same family as beta-carotene, responsible among other things for the yellow-orange color of marigold flowers, from which they are industrially extracted. The human body cannot synthesize them on its own — they must come from diet (leafy green vegetables, corn, egg yolks) or supplementation. What makes them especially interesting in the context of the eye is that they are the only carotenoids that accumulate in significant amounts specifically in the macula of the retina — giving it, in fact, the yellowish tint from which its name derives (macula lutea, "yellow spot").

To understand today's evidence, we need to go back to the late 1990s and early 2000s, when the American National Eye Institute ran a large study called AREDS (Age-Related Eye Disease Study). The supplement formula tested at the time contained high doses of vitamin C, vitamin E, beta-carotene, and zinc (with a small addition of copper) — and it's this original combination that became the basis for many of today's "eye" supplements.

This distinction — AREDS with beta-carotene versus AREDS2 with lutein and zeaxanthin — is key to correctly reading the results of the Cochrane review described in the next section, because the two formulas don't carry exactly the same strength of evidence.

This is the most important, and most often overlooked, distinction in this topic: the OR 0.72 result cited above applies to the entire, multi-ingredient AREDS-type antioxidant formula (with beta-carotene) — not to lutein and zeaxanthin isolated as a standalone supplement. When the Cochrane review analyzed lutein and zeaxanthin separately (i.e., in a configuration similar to AREDS2, without beta-carotene), the results were markedly less convincing: the relative risk of AMD progression was close to 1.0 across most of the measures analyzed, and differences in quality of life between groups were negligible. Importantly, the quality of this specific evidence was rated as low-certainty — clearly lower than for the multi-ingredient formula.

For completeness, it's worth adding two more findings from the same review: zinc alone showed a modest but noticeable protective effect against progression to advanced AMD (OR 0.83), while the evidence for vitamin E alone remained highly uncertain — the trials analyzed recorded just 7 cases of progression to advanced disease, far too few events to draw reliable conclusions.

AMD is a rare example of a topic where supplement marketing and solid science partly overlap, but diverge on details that carry real clinical weight. The Cochrane review does confirm that a specific, multi-ingredient antioxidant formula helps slow disease progression — but only in people already diagnosed with intermediate-stage AMD, and largely thanks to the combination of ingredients, not lutein or zeaxanthin on their own. Buying lutein alone "just in case" with healthy eyes isn't supported today by the same evidence used to advertise it.